ArticleEsophagus : official journal of the Japan Esophageal Society2023
Ramelteon and suvorexant for postoperative delirium in elderly patients with esophageal cancer.
Article in Esophagus : official journal of the Japan Esophageal Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Efficacy of Dexmedetomidine as an Adjuvant to Ropivacaine for Intercostal Nerve Block in Elderly Patients Undergoing Video-Assisted Thoracoscopic Esophagectomy: A randomized Double-Blinded Trial.Journal of pain research · 2025Trial
- Ramelteon and Mortality in Patients With Sepsis and Cancer: Insights From a Propensity-Matched Analysis of the MIMIC-IV Database.Cancer medicine · 2026Article
- Investigating the impact of ramelteon on all-cause mortality in ischemic stroke ICU patients: a retrospective propensity-matched study from the MIMIC-IV database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparative evaluation of transmediastinal and minimally invasive McKeown esophagectomy for esophageal cancer: perioperative and oncologic outcomes.Frontiers in oncology · 2025Article
- Essential updates 2022/2023: Recent advances in perioperative management of esophagectomy to improve operative outcomes.Annals of gastroenterological surgery · 2024Review
- Reply to: The use of drugs to prevent postoperative delirium in elderly patients with radical esophagectomy.Esophagus : official journal of the Japan Esophageal Society · 2024Article
- The use of drugs to prevent postoperative delirium in elderly patients with radical esophagectomy.Esophagus : official journal of the Japan Esophageal Society · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no clear evidence on the prevention of postoperative delirium with pharmacotherapy in elderly patients with esophageal cancer. This retrospective study aimed to evaluate the efficacy of ramelteon and suvorexant in preventing postoperative delirium in this patient group.
methodsData on 251 patients who received radical esophagectomy for thoracic esophageal cancer were collected from January 2010 to September 2021. In total, 74 patients did not receive preventive intervention, and 177 received ramelteon and suvorexant. After propensity score matching, the rate of postoperative delirium was compared between the two groups.
resultsSeventy-two well-balanced patients in each group demonstrated similar clinical and pathological characteristics. The mean ages of the intervention and control groups were 70.8 and 70.3 years, respectively. All the patients underwent McKeown esophagectomy, and in the volume of intraoperative blood loss or operative time did not significantly differ between the two groups. The incidence rates of postoperative hyperactive delirium were 7% (5/72) in the intervention group and 32% (23/72) in the control group (p < 0.001). No severe adverse event potentially attributable to the intervention drug was observed. The multivariate analysis showed that the use of ramelteon and suvorexant was the only independent protective factor against postoperative delirium (hazard ratio 0.157, 95% CI 0.055-0.448, p < 0.001).
conclusionsRamelteon and suvorexant may play an important role in reducing postoperative delirium in elderly patients with esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.